Drug profile · INN
selexipag
UPTRAVI
selexipag (UPTRAVI) is a prostanoid ip receptor agonist. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — selexipag
- US status
- approved
- Class
- Blood and blood forming organs (B01)
- Route
- ORAL
- Patents
- 1
- Programs
- 0
- Data quality
- 0.84
Quick answer
selexipag (UPTRAVI) is a prostanoid ip receptor agonist. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Prostanoid IP receptor agonist
Primary target: Prostacyclin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is selexipag?
selexipag (UPTRAVI) is a prostanoid ip receptor agonist. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for selexipag?
UPTRAVI is a marketed brand name for selexipag. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of selexipag?
selexipag has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.